Pioneering Macrophage Cell Therapy for Transformative Outcomes in Inflammatory Organ Diseases

Inflammatory organ disease affects millions of patients worldwide. We aim to treat these patients, for example by helping patients with liver cirrhosis avoiding the need for a transplantation.

The Science +

Harnessing the healing power of the macrophage

Resolution Therapeutics is developing macrophage cell therapies to treat diseases characterised by life-threatening inflammatory organ damage. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, manufacture and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes.

Latest News

13/11/2023

Resolution Therapeutics’ founders present clinical proof-of-concept for macrophage cell therapy in end-stage liver disease at AASLD

Edinburgh and London, UK, 13 November 2023 - 1-year results of the MATCH Phase 2 trial of macrophage cell therapy in cirrhosis presented at AASLD

READ MORE +
14/08/2023

Resolution Therapeutics appoints Dr. Amir Hefni as Chief Executive Officer

London, 14 August 2023 - Resolution Therapeutics announces the appointment of Dr. Amir Hefni as Chief Executive Officer

READ MORE +
10/07/2023

Resolution Therapeutics Strengthens its Executive Team with the Appointment of Simon Ramsden as Chief Financial Officer

London, 10 July 2023 – Resolution Therapeutics announces the appointment of Simon Ramsden as Chief Financial Officer.

READ MORE +
26/06/2023

Resolution Therapeutics Strengthens its Team with Senior Appointments

London, 26 June 2023 - Resolution Therapeutics announces the appointment of key senior hires in intellectual property, human resources and clinical operations

READ MORE +
02/05/2023

Resolution Appoints Liver Disease Expert, Dr Clifford A. Brass, as Chief Medical Officer

London, 2 May 2023 – Resolution Therapeutics announces the appointment of Dr. Clifford A. Brass as Chief Medical Officer

READ MORE +

CEO's Statement

Resolution is at the forefront of a new kind of cell therapy. We’re treating inflammatory organ disease with macrophages, the cells that the body uses to resolve injury and heal wounds. Our work builds on a huge body of science understanding the role of macrophages as orchestrators of the wound healing process; coupled with our world-leading founders, a top-quality scientific staff and proprietary insight into macrophage biology and manufacturing, we are poised to improve the lives of countless patients worldwide.

Amir Hefni CEO